The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?
February 2017
Patients, caregivers, and providers need education on immunotherapy treatment, support in patient-provider communications as well as support in mitigating the financial impact of immunotherapy treatment.
An oncologist provides insight on his experience with using CAR-T therapy in the clinic and his prediction for the future of this revolutionary treatment.
Community oncologists will be at the forefront of using immunotherapies and will need to be strong advocates for greater information and affordability of therapies.
Immunotherapy treatments are not without side effects. What do patients and their families need to know so they are more aware?
An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
A note from the editor-in-chief.
Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.
AJMCtv® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Balancing Efficacy and Safety in BTKi Therapy
5
